Aldesleukin is under clinical development by Iltoo Pharma and currently in Phase II for Miscarriage. According to GlobalData, Phase II drugs for Miscarriage does not have sufficient historical data to build an indication benchmark PTSR for Phase II. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Aldesleukin LoA Report. Buy the report here.

Smarter leaders trust GlobalData

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Aldesleukin overview

ILT-101 is under development for the treatment of autoimmune and inflammatory diseases including type I diabetes, acute respiratory distress syndrome due to Coronavirus disease 2019 (COVID-19), relapsing remitting multiple sclerosis, recurrent miscarriage, systemic lupus erythematosus, allergic rhino-conjunctivitis, rheumatoid arthritis, ankylosing spondylitis, systemic lupus erythematosus, psoriasis, Behcet disease, Wegener granulomatosis, Gougerot-sjogren, systemic sclerosis, idiopathic thrombocytopenic purpur, bipolar disorder and amyotrophic lateral sclerosis. It is administered by subcutaneous route and formulated as powder for solution as an injection. The drug candidate is a human recombinant Interleukin-2 which acts by targeting interleukin receptor2. It was also under development for Takayasu disease, Crohn's disease, ulcerative colitis, autoimmune hepatitis and sclerosing cholangitis.

For a complete picture of Aldesleukin’s drug-specific PTSR and LoA scores, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.